Effect of Quercetin in Treatment of Periodontitis

Assiut University

Status and phase: Not yet enrolling; Phase 1

Conditions: Inflammation Gum

Treatments: Drug: Quercetin; Device: scaling and root planing

Study type: Interventional

Funder types: Other

Identifiers

NCT05928546

Quercetin in periodontitis

Details and patient eligibility

About

Periodontitis is an immune-inflammatory disease affecting the supporting structures of the teeth. It is a disease of multifactorial etiology, with microbial, genetic, environmental and host factors involved, with the release of oxygen-free radicals by the inflammatory cells. Quercetin, have shown potential antimicrobial activity, lowering of inflammatory markers, cholesterol reduction and inhibiting bone loss. However, this data has largely been obtained from in vitro and animal studies, but data from human studies are limited.

Full description

Quercetin has been found to decrease the extracellular matrix degradation, promote wound healing when tested in gingival fibroblasts, and showed excellent antibacterial properties. It also possesses antioxidant effect which can be explored to restrict the inflammation in periodontitis. Despite the beneficial effects of Quercetin, its poor aqueous solubility and poor bioavailability result in limited absorption, so scientists have worked on improving the bioavailability of Quercetin using various approaches, such as nanosuspension , self-nano emulsifying systems , microemulsion , solid lipid nanoparticles and cyclodextrin complexes. The combination of oils and emulsifiers enhances the absorption of Quercetin. Hence, nanoemulsion could be a suitable drug delivery vehicle for the loading of Quercetin. Nanoemulsions are more beneficial than microemulsions, as they have high kinetic stability and a smaller droplet size. Therefore, the present study will investigate the efficacy of nanoemulgel of quercetin as adjunct to conventional therapy in treatment of periodontitis.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Inclusion criteria:

  • Patients with periodontitis stage ( Ⅰ & Ⅱ ). Stage I have CAL 1 to 2mm with no tooth loss and probing depth ≤4 mm. Stage II have CAL 3 to 4mm with no tooth loss and probing depth ≤5 mm..
  • Patients who have teeth with both mesial and distal neighboring teeth .
  • Patient with more than 20 natural teeth .
  • Patient free from any systemic disease that may effect the periodontal status according to the criteria of Cornell Medical Index and its modification.

Exclusion criteria

• Long-term therapy with medications within a month prior to enrollment that could affect periodontal status or healing.
• Pregnant woman and lactating mothers .
• Patients with a history of traumatic occlusion.
• Teeth with both endo-perio lesion .
• Patients with previous periodontal treatment including scaling and root planing and periodontal surgery in the last 3 and 6 months, respectively .

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups, including a placebo group

Group(I):scaling and root planing only

Placebo Comparator group

Description:

10 sites will receive non-surgical periodontal therapy (scaling and root planing) .

Treatment:

Device: scaling and root planing

Group(Ⅱ):scaling and root planing with application of quercetin nanoemulgel

Active Comparator group

Description:

10 sites will receive non-surgical periodontal therapy followed by the application of quercetin nanoemulgel local delivery 2 times one at the day of non-surgical periodontal therapy and after 2 weeks.

Treatment:

Device: scaling and root planing

Drug: Quercetin